Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of “Hold” from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been given an average rating of “Hold” by the fourteen research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $15.55.

FOLD has been the subject of a number of research reports. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. The Goldman Sachs Group lifted their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald lowered Amicus Therapeutics from an “overweight” rating to a “hold” rating and reduced their price target for the company from $21.00 to $14.50 in a report on Friday, December 19th.

Insider Buying and Selling at Amicus Therapeutics

In other news, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider owned 439,318 shares in the company, valued at approximately $4,463,470.88. This trade represents a 14.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Michael Clark sold 25,642 shares of Amicus Therapeutics stock in a transaction on Friday, December 19th. The shares were sold at an average price of $14.17, for a total transaction of $363,347.14. Following the completion of the sale, the insider directly owned 245,690 shares of the company’s stock, valued at approximately $3,481,427.30. The trade was a 9.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 420,450 shares of company stock valued at $4,730,250 over the last three months. 2.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors have recently bought and sold shares of FOLD. Vestal Point Capital LP lifted its position in shares of Amicus Therapeutics by 178.4% in the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after buying an additional 7,625,000 shares during the last quarter. Norges Bank acquired a new stake in Amicus Therapeutics in the 2nd quarter worth approximately $18,540,000. Qube Research & Technologies Ltd lifted its holdings in Amicus Therapeutics by 223.9% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock worth $19,865,000 after purchasing an additional 2,396,410 shares during the last quarter. State Street Corp boosted its position in Amicus Therapeutics by 21.5% during the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock worth $66,285,000 after purchasing an additional 2,049,078 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in Amicus Therapeutics during the third quarter valued at approximately $15,534,000.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $14.28 on Friday. The company has a 50 day simple moving average of $12.23 and a 200-day simple moving average of $9.29. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of -356.79 and a beta of 0.42. Amicus Therapeutics has a 52-week low of $5.51 and a 52-week high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 earnings per share. Equities research analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.